NCT03314805View on ClinicalTrials.gov

PG2 Treatment Among Stage II/III Breast Cancer Patients Receiving Adjuvant Chemotherapy

PHASE2CompletedINTERVENTIONAL
Enrollment

67

Participants

Timeline

Start Date

March 1, 2018

Primary Completion Date

May 26, 2021

Study Completion Date

August 27, 2021

Conditions
Cancer-related FatigueNeutropenia, Malignant
Interventions
DRUG

Astragalus polysaccharides 500 mg

PG2 (500 mg in 500 ml saline), 3 days via i.v. infusion per chemotherapy cycle

DRUG

Placebo

500 ml saline, 3 days via i.v. infusion per chemotherapy cycle

PROCEDURE

EC Chemotherapy

Epirubicin plus Cyclophosphamide every 21 days

Trial Locations (5)

105

Chang Gung Memorial Hospital, Taipei Branch, Taipei

204

Chang Gung Memorial Hospital, Lovers Lake branch, Keelung

333

Chang Gung Memorial Hospital, Linkou Branch, Taoyuan

824

E-Da Cancer Hospital, Kaohsiung City

833

Chang Gung Memorial Hospital, Kaohsiung Branch, Kaohsiung City

Sponsors
All Listed Sponsors
lead

PhytoHealth Corporation

INDUSTRY